Abstracts Archive - Page 267 of 1683 - ATC Abstracts

2021 American Transplant Congress
Impact of Traveling for Transplant on Access to and Outcomes from Kidney and Liver Transplantation
K. Ross-Driscoll¹, R. Lynch¹, D. Axelrod², R. Patzer¹
¹Emory University, Atlanta, GA, ²University of Iowa, Ames, IA
*Purpose: Newly developed transplant referral regions (TRRs) can be used to understand how and why patients travel outside of their home transplant center to receive…
2021 American Transplant Congress
Kidney Transplantation in Times of Covid-19 – Decision Analysis in the Canadian Context
I. Yanev¹, M. Gagnon¹, M. Cheng², S. Paraskevas², D. Kumar³, A. Dragomir⁴, R. Sapir-Pichhadze⁴
¹McGill University, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Research Institute of McGill University Health Centre, Montreal, QC, Canada
*Purpose: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted the field of transplantation across Canada. In this study, we outline the implications of COVID-19 related…
2021 American Transplant Congress
Elevated Tacrolimus Levels in Hospitalized Organ Transplant Recipients with COVID-19
K. Mecadon¹, A. Hardesty², K. Vieira³, R. Rogers³, B. Merhi⁴, A. J. Osband⁵, G. Bayliss⁴, R. Gohh⁴, P. Morrissey⁵, D. Farmakiotis³
¹Department of Pharmacy, Rhode Island Hospital, Providence, RI, ²Department of Internal Medicine, Residency, Warren Alpert Medical School of Brown University, Providence, RI, ³Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI, ⁴Division of Nephrology, Warren Alpert Medical School of Brown University, Providence, RI, ⁵Department of Surgery (Transplantation), Warren Alpert Medical School of Brown University, Providence, RI
*Purpose: The effect of COVID-19 on immunosuppressant drug levels in organ transplant recipients (OTRs) has not been adequately studied.*Methods: We retrospectively studied hospitalized adult (>18-year-old)…
2021 American Transplant Congress
Quantification of Multiple Isotypes of Anti-SARS-CoV-2 Antibodies in Kidney Transplant Recipients
J. S. Maltzman¹, L. Wang¹, P. Ahearn¹, T. Yalamarti¹, M. Menon², Y. Azzi³, M. Melcher¹, M. Fernandez-Vina¹, R. Bray⁴, H. Gebel⁴, E. Woodle⁵, E. Akalin³, A. Girnita¹, P. Cravedi²
¹Stanford University, Palo Alto, CA, ²Icahn School of Medicine, NYC, NY, ³Einstein School of Medicine, NYC, NY, ⁴Emory University, Atlanta, GA, ⁵University of Cincinnati, Cincinnati, OH
*Purpose: Solid organ transplant recipients are at increased risk of severe outcomes with infection by SARS-CoV-2, the etiologic agent of COVID-19. Antibodies directed against the…
2021 American Transplant Congress
Monoclonal Antibodies for Covid-19 in Patients with Solid Organ Transplant Recipients
L. Hasan¹, H. Hardgrave², T. Osborn³, R. Dare¹, L. Burdine⁴, E. Giorgakis⁴, J. Rico¹
¹Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, ²University of Arkansas for Medical Sciences, Little Rock, AR, ³Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Transplant surgery, University of Arkansas for Medical Sciences, Little Rock, AR
*Purpose: The FDA has issued Emergency Use Authorization (EUA) for monoclonal antibodies for the treatment of mild to moderate COVID-19 in patients at risk for…
2021 American Transplant Congress
Comparison of Outcomes of Living Donor Liver Transplantation for Biliary Atresia Patients with and without Kasai Portoenterostomy
T. Kanmaz¹, O. Andacoglu¹, Y. Yankol², C. Karatas¹, N. Mecit¹, K. Acarli³, M. Kalayoglu¹
¹Koc University, Istanbul, Turkey, ²University of Wisconsin, Madison, WI, ³Memorial Hospital, Istanbul, Turkey
*Purpose: We evaluated 10 year outcomes and the potential predictors of outcomes after living donor liver transplant (LT) for biliary atresia (BA) patients with and…
2021 American Transplant Congress
Hepatoportoenterostomy versus Primary Liver Transplantation for Biliary Atresia: A Review of the National Experience
D. Yoeli¹, R. A. Choudhury¹, S. S. Sundaram², C. L. Mack², J. P. Roach³, F. M. Karrer⁴, M. E. Wachs¹, M. A. Adams¹
¹Transplant Surgery, University of Colorado and Children's Hospital Colorado, Aurora, CO, ²Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado and Children's Hospital Colorado, Aurora, CO, ³Pediatric Surgery, University of Colorado, Aurora, CO, ⁴Pediatric Surgery, University of Colorado and Children's Hospital Colorado, Aurora, CO
*Purpose: Kasai hepatoportoenterostomy (HPE) followed by liver transplantation (LT) if needed is the standard of care for children with biliary atresia (BA). Some, however, have…
2021 American Transplant Congress
Evaluation of Safety and Efficacy of PCSK9 Inhibitors in Solid Organ Transplant Recipients: Experience at a Large Multi-organ Transplant Center
A. Ucci¹, M. Norris², J. Trofe-Clark², T. Fallah², M. Meck¹, R. Samudralwar¹, M. V. Genuardi³
¹Hospital of Univ of Pennsylvania, Philadelphia, PA, ²Penn Transplant Institute, Hospital of Univ of Pennsylvania, Philadelphia, PA, ³Cardiovascular Medicine Div, Hospital of Univ of Pennsylvania, Philadelphia, PA
*Purpose: The aim of the study was to characterize the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in solid organ transplant…
2021 American Transplant Congress
Postoperative Tracheostomy as a Predictor of Poor Clinical Outcomes in Lung Transplantation
E. C. Klipsch, T. J. Hathaway, D. Roe, C. Hage, M. Duncan, R. S. Mangus
Indiana University School of Medicine, Indianapolis, IN
*Purpose: Tracheostomies are commonly performed postoperatively in lung transplant recipients to provide ventilation for prolonged periods, and with relatively few studies detailing these patients’ outcomes…
2021 American Transplant Congress
The Impact of Tacrolimus IPV and TTR on the Development of De Novo Donor-specific Antibodies in Kidney Transplant Recipients
D. Xu¹, K. Richards¹, K. Zheng¹, H. Patel², F. Cardarelli², J. A. Pena³, A. Aala²
¹Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, ²Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ³Pathology, Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: High intrapatient variability (IPV) and low time in therapeutic range (TTR) of tacrolimus (TAC) may increase the risk of developing de novo donor-specific antibodies…